Skip Navigation

Social History of Medicine 2002 15(1):137-158; doi:10.1093/shm/15.1.137
© 2002 by Society for the Social History of Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Daemmrich, A.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

A Tale of Two Experts: Thalidomide and Political Engagement in the United States and West Germany

Arthur Daemmrich1

1 Chemical Heritage Foundation, 315 Chestnut Street, Philadelphia, PA 19106-2702, USA. E-mail: arthurd{at}chemheritage.org

The physicians, Widukind Lenz and Frances Kelsey, played crucial roles in the thalidomide drama of the early 1960s. Widespread use of the drug in West Germany was only halted when the paediatrician, Lenz, publicized its association with the birth of nearly 4,000 children exhibiting abnormal limb growth. Few cases were reported in the United States because Kelsey, a medical officer at the US Food and Drug Administration, repeatedly delayed thalidomide's marketing approval. Experts in both countries were expected to demonstrate publicly the professional ‘objectivity’ of medicine and the institutional ‘disinterestedness’ of regulatory bodies. These norms were invoked both by industry representatives seeking to undermine the two experts and by critics desiring stronger regulatory controls. Comparing Lenz with Kelsey demonstrates how institutional structures shape an expert's social and scientific roles. While the United States provided important protection from external pressure for Kelsey through her regulatory position at the FDA, Lenz was open to sharp criticism, especially when giving expert testimony during a lengthy court trial. The degree of exposure to politically motivated attacks differed for these two experts; they nevertheless faced similar threats to their professional credibility and personal integrity when they publicized links between thalidomide and birth defects.

Keywords: Contergan; Thalidomide; drug regulation; credibility; expertise; FDA; Frances Kelsey; Widukind Lenz


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Science Technology Human ValuesHome page
J. Abraham and C. Davis
Deficits, Expectations and Paradigms in British and American Drug Safety Assessments: Prising Open the Black Box of Regulatory Science
Science Technology Human Values, July 1, 2007; 32(4): 399 - 431.
[Abstract] [PDF]

Home page
 Soc Hist MedHome page
J. Abraham and C. Davis
Testing Times: The Emergence of the Practolol Disaster and its Challenge to British Drug Regulation in the Modern Period
Soc Hist Med, April 1, 2006; 19(1): 127 - 147.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.